| 1 | Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases | 4.0 | 5 | Citations (PDF) |
| 2 | Predicting blood pressure response to renal denervation based on a new approach | 2.1 | 1 | Citations (PDF) |
| 3 | Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials | 3.0 | 9 | Citations (PDF) |
| 4 | Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications | 3.4 | 9 | Citations (PDF) |
| 5 | The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial | 0.8 | 16 | Citations (PDF) |
| 6 | Two-year nighttime blood pressure changes after radiofrequency renal denervation: pooled results from the SPYRAL HTN trials | 3.0 | 3 | Citations (PDF) |
| 7 | Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial | 4.8 | 13 | Citations (PDF) |
| 8 | REDUCING HYPERTENSIVE URGENCY THROUGH RADIOFREQUENCY RENAL DENERVATION: INSIGHTS FROM SPYRAL HTN-OFF AND -ON MED TRIALS | 2.1 | 0 | Citations (PDF) |
| 9 | RETINAL NEURODEGENERATION IN PATIENTS WITH TREATMENT RESISTANT HYPERTENSION ASSESSED BY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY | 2.1 | 0 | Citations (PDF) |
| 10 | EFFECTS OF THE GLP-1 RA SEMAGLUTIDE ON VASCULAR STRUCTURE AND FUNCTION IN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF A PROSPECTIVE RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY | 2.1 | 2 | Citations (PDF) |
| 11 | PREDICTORS OF BLOOD PRESSURE RESPONSE TO ULTRASOUND-BASED RENAL DENERVATION BY APPLYING A NEW DEFINITION OF RESPONSE | 2.1 | 0 | Citations (PDF) |
| 12 | Renal denervation is effective in reducing blood pressure in patients with CKD | 3.4 | 5 | Citations (PDF) |
| 13 | Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease | 3.4 | 2 | Citations (PDF) |
| 14 | Endothelial function in high-risk patients with ezetimibe therapy | 3.1 | 0 | Citations (PDF) |
| 15 | Effects of Combination Treatment on Renal Endothelial Function in Type 2 Diabetes Mellitus | 2.5 | 0 | Citations (PDF) |
| 16 | On-treatment systolic blood pressure and preserved kidney function in hypertensive patients with proteinuria. The VALUE Trial | 1.7 | 1 | Citations (PDF) |
| 17 | Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program | 18.0 | 37 | Citations (PDF) |
| 18 | Relation between waist circumference and the renal hemodynamic in healthy individuals | 3.2 | 3 | Citations (PDF) |
| 19 | Blood pressure reduction after renal denervation in patients with or without chronic kidney disease | 3.4 | 7 | Citations (PDF) |
| 20 | Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence | 3.7 | 20 | Citations (PDF) |
| 21 | Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension | 1.6 | 8 | Citations (PDF) |
| 22 | Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED | 6.6 | 33 | Citations (PDF) |
| 23 | Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial | 18.0 | 54 | Citations (PDF) |
| 24 | Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups | 2.1 | 22 | Citations (PDF) |
| 25 | Is GFR decline induced by SGLT2 inhibitor of clinical importance? | 9.4 | 7 | Citations (PDF) |
| 26 | Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney | 1.7 | 1 | Citations (PDF) |
| 27 | Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial | 33.0 | 150 | Citations (PDF) |
| 28 | Progressive Kidney Failure by Angiotensinogen Inactivation in the Germline | 6.6 | 0 | Citations (PDF) |
| 29 | Renal adaptation in pre-obesity patients with hypertension | 2.1 | 1 | Citations (PDF) |
| 30 | O91 SIGNIFICANT NIGHTTIME BLOOD PRESSURE REDUCTIONS FOLLOWING RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION: POOLED ANALYSIS FROM THE SPYRAL HTN TRIALS | 2.1 | 0 | Citations (PDF) |
| 31 | Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis | 18.0 | 57 | Citations (PDF) |
| 32 | Renal Denervation Lowers Nighttime Blood Pressure in True Resistant Hypertension | 6.6 | 5 | Citations (PDF) |
| 33 | Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial | 33.0 | 94 | Citations (PDF) |
| 34 | PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease | 2.8 | 4 | Citations (PDF) |
| 35 | Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease | 0.8 | 53 | Citations (PDF) |
| 36 | Renal denervation in patients with chronic kidney disease: current evidence and future perspectives | 0.8 | 35 | Citations (PDF) |
| 37 | Sex Differences in Blood Pressure and Potential Implications for Cardiovascular Risk Management | 6.6 | 28 | Citations (PDF) |
| 38 | Impact of type 1 diabetes and its duration on wall-to-lumen ratio and blood flow in retinal arterioles | 2.5 | 10 | Citations (PDF) |
| 39 | CRT-600.06 Cost-Effectiveness of Catheter-Based Radiofrequency Renal Denervation for the Treatment of Uncontrolled Hypertension: An Analysis for the UK Based on Recent Clinical Evidence | 3.0 | 1 | Citations (PDF) |
| 40 | Renal Denervation: A Practical Guide for Health Professionals Managing Hypertension | 1.4 | 12 | Citations (PDF) |
| 41 | Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study | 6.6 | 67 | Citations (PDF) |
| 42 | Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis | 3.4 | 16 | Citations (PDF) |
| 43 | BLOOD PRESSURE REDUCTION AFTER RENAL DENERVATION IN PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE: THE ERLANGER EXPERIENCE | 2.1 | 0 | Citations (PDF) |
| 44 | HIGH SODIUM INTAKE - EFFECTS ON AFFERENT RENAL NERVE ACTIVITY | 2.1 | 0 | Citations (PDF) |
| 45 | EMPAGLIFLOZIN IMPROVES IMPAIRED SENSITIVITY OF AFFERENT NEURONS WITH RENAL AXONS | 2.1 | 0 | Citations (PDF) |
| 46 | Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE | 6.6 | 35 | Citations (PDF) |
| 47 | Afferent neurons of the kidney with impaired firing pattern in inflammation – role of sodium currents? | 2.3 | 2 | Citations (PDF) |
| 48 | Cost-Effectiveness of Catheter-Based Radiofrequency Renal Denervation for the Treatment of Uncontrolled Hypertension: An Analysis for the UK Based on Recent Clinical Evidence | 0.7 | 0 | Citations (PDF) |
| 49 | Skin sodium content as a predictor of blood pressure response to renal denervation | 3.0 | 8 | Citations (PDF) |
| 50 | Renal denervation: where do we stand and what is the relevance to the nephrologist? | 0.8 | 28 | Citations (PDF) |
| 51 | Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years | 0.8 | 55 | Citations (PDF) |
| 52 | Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial | 2.1 | 12 | Citations (PDF) |
| 53 | Diagnosis and treatment of arterial hypertension 2021 | 5.3 | 91 | Citations (PDF) |
| 54 | The influence of aircraft noise exposure on the systemic and renal haemodynamics | 2.0 | 9 | Citations (PDF) |
| 55 | Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers | 9.4 | 12 | Citations (PDF) |
| 56 | Renale Denervation | 0.4 | 0 | Citations (PDF) |
| 57 | Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk | 9.4 | 29 | Citations (PDF) |
| 58 | The authors reply | 5.3 | 0 | Citations (PDF) |
| 59 | Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium | 18.0 | 73 | Citations (PDF) |
| 60 | Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial | 62.1 | 270 | Citations (PDF) |
| 61 | MO085: 10-Year Clinical Events Avoided in Diabetic and Chronic Kidney Disease Hypertension Patients Treated With Radiofrequency Renal Denervation: Projections Based on 3-Year Data From the Global Symplicity Registry | 0.8 | 0 | Citations (PDF) |
| 62 | Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial | 6.6 | 20 | Citations (PDF) |
| 63 | IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES | 2.1 | 0 | Citations (PDF) |
| 64 | Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial | 2.8 | 10 | Citations (PDF) |
| 65 | Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study | 3.4 | 2 | Citations (PDF) |
| 66 | PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease | 2.2 | 1 | Citations (PDF) |
| 67 | The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial | 2.8 | 31 | Citations (PDF) |
| 68 | Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes | 6.6 | 86 | Citations (PDF) |
| 69 | New strategies to improve clinical outcomes for diabetic kidney disease | 7.1 | 74 | Citations (PDF) |
| 70 | How to measure retinal microperfusion in patients with arterial hypertension | 1.7 | 7 | Citations (PDF) |
| 71 | Reference values of retinal microcirculation parameters derived from a population random sample | 2.5 | 7 | Citations (PDF) |
| 72 | Novel approaches to management of hypertension | 2.2 | 7 | Citations (PDF) |
| 73 | Improved blood pressure control via a novel chronic disease management model of care in sub‐Saharan Africa: Real‐world program implementation results | 2.0 | 18 | Citations (PDF) |
| 74 | Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke | 2.1 | 10 | Citations (PDF) |
| 75 | Renal and Intraglomerular Haemodynamics in Chronic Heart Failure with Preserved and Reduced Ejection Fraction | 3.1 | 14 | Citations (PDF) |
| 76 | Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements | 6.6 | 10 | Citations (PDF) |
| 77 | Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk | 2.1 | 11 | Citations (PDF) |
| 78 | Neurogenic substance P—influences on action potential production in afferent neurons of the kidney? | 2.3 | 2 | Citations (PDF) |
| 79 | Hypertrophic Remodelling of Retinal Arterioles in Patients with Congestive Heart Failure | 3.1 | 5 | Citations (PDF) |
| 80 | Dependency of flow‐mediated vasodilatation from basal nitric oxide activity | 1.1 | 14 | Citations (PDF) |
| 81 | Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study | 2.5 | 34 | Citations (PDF) |
| 82 | Update on Treatment of Hypertension After Renal Transplantation | 4.7 | 11 | Citations (PDF) |
| 83 | Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation | 2.3 | 108 | Citations (PDF) |
| 84 | Nephropathie bei Diabetes | 0.0 | 0 | Citations (PDF) |
| 85 | Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial | 62.1 | 395 | Citations (PDF) |
| 86 | European Society of Hypertension position paper on renal denervation 2021 | 2.1 | 124 | Citations (PDF) |
| 87 | Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von „Renale-Denervations-Zentren (RDZ)“ – Update | 0.2 | 7 | Citations (PDF) |
| 88 | Neurovascular Compression in Arterial Hypertension: Correlation of Clinical Data to 3D-Visualizations of MRI-Findings | 0.5 | 0 | Citations (PDF) |
| 89 | Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension | 2.3 | 54 | Citations (PDF) |
| 90 | Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications | 2.9 | 25 | Citations (PDF) |
| 91 | Effects of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function in Patients with Chronic Heart Failure | 3.1 | 21 | Citations (PDF) |
| 92 | Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine | 9.4 | 24 | Citations (PDF) |
| 93 | Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension | 4.8 | 15 | Citations (PDF) |
| 94 | Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes | 2.4 | 7 | Citations (PDF) |
| 95 | Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension | 2.1 | 43 | Citations (PDF) |
| 96 | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure | 9.4 | 51 | Citations (PDF) |
| 97 | Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials | 2.2 | 52 | Citations (PDF) |
| 98 | Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage | 1.7 | 9 | Citations (PDF) |
| 99 | Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes | 4.0 | 19 | Citations (PDF) |
| 100 | Neurogenic tachykinin mechanisms in experimental nephritis of rats | 2.3 | 8 | Citations (PDF) |
| 101 | Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids | 11.3 | 35 | Citations (PDF) |
| 102 | Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment | 2.1 | 4 | Citations (PDF) |
| 103 | Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin | 0.2 | 1 | Citations (PDF) |
| 104 | Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials | 2.1 | 13 | Citations (PDF) |
| 105 | 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation | 3.0 | 65 | Citations (PDF) |
| 106 | 3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension | 1.7 | 11 | Citations (PDF) |
| 107 | Renal Denervation in High-Risk Patients With Hypertension | 2.3 | 114 | Citations (PDF) |
| 108 | Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial | 62.1 | 557 | Citations (PDF) |
| 109 | Changes in Stroke Volume After Renal Denervation | 6.6 | 16 | Citations (PDF) |
| 110 | Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation | 2.5 | 15 | Citations (PDF) |
| 111 | Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension | 3.0 | 98 | Citations (PDF) |
| 112 | Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design | 2.8 | 39 | Citations (PDF) |
| 113 | Influence of Age on Upper Arm Cuff Blood Pressure Measurement | 6.6 | 38 | Citations (PDF) |
| 114 | Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension | 2.3 | 24 | Citations (PDF) |
| 115 | Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography | 3.4 | 19 | Citations (PDF) |
| 116 | Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies | 2.2 | 90 | Citations (PDF) |
| 117 | Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial | 2.8 | 29 | Citations (PDF) |
| 118 | Confounding Factors in Renal Denervation Trials | 6.6 | 45 | Citations (PDF) |
| 119 | Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study | 1.2 | 6 | Citations (PDF) |
| 120 | Tissue sodium content in hypertension and related organ damage | 2.1 | 10 | Citations (PDF) |
| 121 | Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy | 6.6 | 25 | Citations (PDF) |
| 122 | Renal Denervation for Treating Hypertension | 3.0 | 83 | Citations (PDF) |
| 123 | Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation | 2.0 | 4 | Citations (PDF) |
| 124 | Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers | 2.5 | 11 | Citations (PDF) |
| 125 | Europäische Hypertonieleitlinien 2018 – was ändert sich? | 0.4 | 3 | Citations (PDF) |
| 126 | Renal Denervation Update From the International Sympathetic Nervous System Summit | 2.3 | 100 | Citations (PDF) |
| 127 | Tissue sodium content in patients with type 2 diabetes mellitus | 2.4 | 31 | Citations (PDF) |
| 128 | Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial | 18.0 | 117 | Citations (PDF) |
| 129 | Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry | 2.2 | 278 | Citations (PDF) |
| 130 | Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk | 2.2 | 65 | Citations (PDF) |
| 131 | How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial | 9.4 | 104 | Citations (PDF) |
| 132 | Patient preference for therapies in hypertension: a cross-sectional survey of German patients | 2.8 | 80 | Citations (PDF) |
| 133 | Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience | 1.3 | 26 | Citations (PDF) |
| 134 | New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension | 0.9 | 0 | Citations (PDF) |
| 135 | Evidence of neurodegeneration in individuals with only mildly elevated blood pressure | 2.1 | 5 | Citations (PDF) |
| 136 | 1416Combined therapy of empagliflozin and linagliptin is superior to metformin and insulin glargine in improving blood pressure and vascular function in type 2 diabetes | 2.2 | 0 | Citations (PDF) |
| 137 | Left Ventricular Structure in Patients With Mild-to-Moderate CKD—a Magnetic Resonance Imaging Study | 2.5 | 12 | Citations (PDF) |
| 138 | Predictors of atherosclerotic events in patients on haemodialysis:
post hoc
analyses from the AURORA study | 0.8 | 17 | Citations (PDF) |
| 139 | Renal denervation improves 24‐hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance | 2.0 | 22 | Citations (PDF) |
| 140 | Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension | 4.7 | 6 | Citations (PDF) |
| 141 | Retinal capillary and arteriolar changes in patients with chronic kidney disease | 2.5 | 24 | Citations (PDF) |
| 142 | Retinal vascular resistance in arterial hypertension | 1.7 | 16 | Citations (PDF) |
| 143 | Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV | 2.1 | 67 | Citations (PDF) |
| 144 | A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs | 2.9 | 75 | Citations (PDF) |
| 145 | Central arteriovenous anastomosis to treat resistant hypertension | 2.2 | 12 | Citations (PDF) |
| 146 | MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol | 1.9 | 37 | Citations (PDF) |
| 147 | 2018 ESC/ESH Guidelines for the management of arterial hypertension | 2.1 | 2,584 | Citations (PDF) |
| 148 | 4325How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? | 2.2 | 0 | Citations (PDF) |
| 149 | Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease | 6.6 | 31 | Citations (PDF) |
| 150 | Early vascular parameters in the micro- and macrocirculation in type 2 diabetes | 9.4 | 18 | Citations (PDF) |
| 151 | P3210Difference in renal parenchymal perfusion after renal denervation comparing treated vs. non-treated arteries | 2.2 | 0 | Citations (PDF) |
| 152 | European Society of Hypertension position paper on renal denervation 2018 | 2.1 | 44 | Citations (PDF) |
| 153 | Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension | 2.1 | 1 | Citations (PDF) |
| 154 | Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial | 62.1 | 750 | Citations (PDF) |
| 155 | Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial | 62.1 | 698 | Citations (PDF) |
| 156 | SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial | 9.4 | 175 | Citations (PDF) |
| 157 | Individualised treatment targets in patients with type-2 diabetes and hypertension | 9.4 | 20 | Citations (PDF) |
| 158 | 2018 ESC/ESH Guidelines for the management of arterial hypertension | 2.2 | 8,913 | Citations (PDF) |
| 159 | Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials | 2.2 | 120 | Citations (PDF) |
| 160 | Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success | 4.0 | 14 | Citations (PDF) |
| 161 | Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD | 0.4 | 184 | Citations (PDF) |
| 162 | Low dose‐eplerenone treatment decreases aortic stiffness in patients with resistant hypertension | 2.0 | 32 | Citations (PDF) |
| 163 | A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation | 9.4 | 133 | Citations (PDF) |
| 164 | Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension | 2.1 | 19 | Citations (PDF) |
| 165 | Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future | 2.2 | 112 | Citations (PDF) |
| 166 | Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials | 62.1 | 306 | Citations (PDF) |
| 167 | Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes | 5.3 | 81 | Citations (PDF) |
| 168 | Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients | 1.4 | 75 | Citations (PDF) |
| 169 | Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension | 6.6 | 52 | Citations (PDF) |
| 170 | Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients | 6.6 | 38 | Citations (PDF) |
| 171 | Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus | 18.0 | 138 | Citations (PDF) |
| 172 | Accuracy of Cuff-Measured Blood Pressure | 2.3 | 263 | Citations (PDF) |
| 173 | Arterielle Hyper- und Hypotonie assoziiert mit Psychopharmaka: eine Risikobewertung basierend auf den Fachinformationen | 0.2 | 12 | Citations (PDF) |
| 174 | Hypertonie und Dyslipidämie | 0.4 | 1 | Citations (PDF) |
| 175 | Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis | 2.6 | 11 | Citations (PDF) |
| 176 | Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension | 2.0 | 2 | Citations (PDF) |
| 177 | Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial | 62.1 | 715 | Citations (PDF) |
| 178 | Retinal capillary rarefaction in patients with untreated mild-moderate hypertension | 2.0 | 49 | Citations (PDF) |
| 179 | MP089EFFECTS OF THE NO SYNTHASE INHIBITOR RONOPTERIN (VAS203) ON RENAL FUNCTION IN HEALTHY VOLUNTEERS | 0.8 | 0 | Citations (PDF) |
| 180 | Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension | 2.8 | 21 | Citations (PDF) |
| 181 | Early Signs of End‐Organ Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients | 1.6 | 11 | Citations (PDF) |
| 182 | The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes | 1.2 | 8 | Citations (PDF) |
| 183 | Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension | 2.1 | 24 | Citations (PDF) |
| 184 | Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension | 4.0 | 22 | Citations (PDF) |
| 185 | The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence | 2.1 | 9 | Citations (PDF) |
| 186 | Non-invasive Renal Denervation: Update on External Ultrasound Approaches | 4.7 | 10 | Citations (PDF) |
| 187 | Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment | 1.2 | 20 | Citations (PDF) |
| 188 | Renal denervation in hypertensive patients not on blood pressure lowering drugs | 2.8 | 21 | Citations (PDF) |
| 189 | Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial | 7.5 | 26 | Citations (PDF) |
| 190 | Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction | 2.0 | 34 | Citations (PDF) |
| 191 | Two‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study | 2.0 | 3 | Citations (PDF) |
| 192 | Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry | 2.0 | 4 | Citations (PDF) |
| 193 | Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients | 2.0 | 21 | Citations (PDF) |
| 194 | Diabetes und Hypertonie | 0.2 | 0 | Citations (PDF) |
| 195 | Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry | 2.0 | 25 | Citations (PDF) |
| 196 | Externally Delivered Focused Ultrasound for Renal Denervation | 3.0 | 34 | Citations (PDF) |
| 197 | Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation | 4.0 | 59 | Citations (PDF) |
| 198 | Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus | 2.3 | 26 | Citations (PDF) |
| 199 | Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin‐Converting Enzyme Inhibitors: The Prospective <scp>EARLY</scp> Registry | 2.0 | 10 | Citations (PDF) |
| 200 | Effect of aliskiren on vascular remodelling in small retinal circulation | 2.1 | 14 | Citations (PDF) |
| 201 | The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry | 2.0 | 5 | Citations (PDF) |
| 202 | Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension | 2.1 | 119 | Citations (PDF) |
| 203 | New developments in the pathogenesis of obesity-induced hypertension | 2.1 | 75 | Citations (PDF) |
| 204 | FO022EFFECTS OF LINAGLIPTIN ON EARLY ALTERATIONS OF RENAL ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE-2 DIABETES | 0.8 | 3 | Citations (PDF) |
| 205 | FP650NON-TRADITIONAL CARDIOVASCULAR RISK FACTORS PREDOMINATE IN HEMODIALYSIS PATIENTS WITH PRE-EXISTIN CARDIOVASCULAR DISEASE | 0.8 | 1 | Citations (PDF) |
| 206 | Managing Treatment-Resistant Patients | 2.3 | 3 | Citations (PDF) |
| 207 | Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry | 2.9 | 15 | Citations (PDF) |
| 208 | Olmesartan Improves Pulse Wave Velocity and Lowers Central Systolic Blood Pressure and Ambulatory Blood Pressure in Patients With Metabolic Syndrome | 2.0 | 9 | Citations (PDF) |
| 209 | Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial | 62.1 | 165 | Citations (PDF) |
| 210 | Wilder's principle: pre-treatment value determines post-treatment response | 2.2 | 83 | Citations (PDF) |
| 211 | New Approaches in the Treatment of Hypertension | 13.1 | 268 | Citations (PDF) |
| 212 | First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension | 6.6 | 188 | Citations (PDF) |
| 213 | Renal Denervation for Resistant Hypertension: Past, Present, and Future | 4.7 | 7 | Citations (PDF) |
| 214 | Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients | 2.8 | 6 | Citations (PDF) |
| 215 | Kardiale Auswirkungen einer Hypertonie | 0.4 | 0 | Citations (PDF) |
| 216 | Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension | 2.8 | 43 | Citations (PDF) |
| 217 | Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin | 2.8 | 15 | Citations (PDF) |
| 218 | Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country | 1.9 | 1 | Citations (PDF) |
| 219 | Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design: Figure 1 | 2.2 | 182 | Citations (PDF) |
| 220 | Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension | 6.6 | 116 | Citations (PDF) |
| 221 | Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging | 1.7 | 11 | Citations (PDF) |
| 222 | Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial | 6.2 | 19 | Citations (PDF) |
| 223 | Urinary Albumin Excretion From Spot Urine Samples Predict All-Cause and Stroke Mortality in Africans | 2.0 | 11 | Citations (PDF) |
| 224 | 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension | 1.7 | 604 | Citations (PDF) |
| 225 | First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients | 2.1 | 13 | Citations (PDF) |
| 226 | Disproportional Decrease in Office Blood Pressure Compared With 24-Hour Ambulatory Blood Pressure With Antihypertensive Treatment | 6.6 | 40 | Citations (PDF) |
| 227 | Improvement of albuminuria after renal denervation | 2.2 | 76 | Citations (PDF) |
| 228 | Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes | 9.4 | 62 | Citations (PDF) |
| 229 | A guide for easy- and difficult-to-treat hypertension | 2.2 | 19 | Citations (PDF) |
| 230 | Renal denervation—implications for chronic kidney disease | 32.8 | 35 | Citations (PDF) |
| 231 | 1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry | 2.2 | 2 | Citations (PDF) |
| 232 | Diagnosis and treatment of resistant hypertension | 1.7 | 3 | Citations (PDF) |
| 233 | Invasive Treatment of Resistant Hypertension: Present and Future | 4.7 | 7 | Citations (PDF) |
| 234 | Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies | 7.5 | 44 | Citations (PDF) |
| 235 | Renal denervation—a valid treatment option despite SYMPLICITY HTN-3 | 35.5 | 11 | Citations (PDF) |
| 236 | Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial | 2.2 | 254 | Citations (PDF) |
| 237 | Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide | 2.1 | 18 | Citations (PDF) |
| 238 | Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress | 4.1 | 21 | Citations (PDF) |
| 239 | Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk | 2.1 | 18 | Citations (PDF) |
| 240 | Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient | 2.1 | 65 | Citations (PDF) |
| 241 | Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes | 2.1 | 5 | Citations (PDF) |
| 242 | Circadian rhythm and day to day variability of serum potassium concentration: a pilot study | 1.5 | 18 | Citations (PDF) |
| 243 | Cost of poor adherence to anti-hypertensive therapy in five European countries | 1.9 | 120 | Citations (PDF) |
| 244 | The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry | 2.5 | 1 | Citations (PDF) |
| 245 | What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension | 3.0 | 48 | Citations (PDF) |
| 246 | Does Renal Artery Supply Indicate Treatment Success of Renal Denervation? | 1.7 | 7 | Citations (PDF) |
| 247 | Ambulatory blood pressure monitoring: Is it mandatory for blood pressure control in treated hypertensive patients? | 2.2 | 20 | Citations (PDF) |
| 248 | Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013) | 0.9 | 10 | Citations (PDF) |
| 249 | International Expert Consensus Statement | 2.3 | 130 | Citations (PDF) |
| 250 | Renal Denervation in Moderate Treatment-Resistant Hypertension | 2.3 | 96 | Citations (PDF) |
| 251 | Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series | 6.6 | 8 | Citations (PDF) |
| 252 | 23
Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients | 6.6 | 378 | Citations (PDF) |
| 253 | Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013) | 1.1 | 28 | Citations (PDF) |
| 254 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension | 2.5 | 26 | Citations (PDF) |
| 255 | Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease | 2.2 | 135 | Citations (PDF) |
| 256 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 1.7 | 369 | Citations (PDF) |
| 257 | The Sympathetic Nervous System in Chronic Kidney Disease | 4.7 | 30 | Citations (PDF) |
| 258 | Ambulatory blood pressure changes and predictors of response in patients undergoing renal sympathetic denervation | 2.2 | 0 | Citations (PDF) |
| 259 | RELAX-AHF: consistency across subgroups and new hypotheses generated | 2.2 | 2 | Citations (PDF) |
| 260 | Central Pulse Pressure Is an Independent Determinant of Vascular Remodeling in the Retinal Circulation | 6.6 | 72 | Citations (PDF) |
| 261 | Poor Glycemic Control Is Related to Increased Nitric Oxide Activity Within the Renal Circulation of Patients With Type 2 Diabetes | 6.2 | 15 | Citations (PDF) |
| 262 | Sensory renal innervation: a kidney-specific firing activity due to a unique expression pattern of voltage-gated sodium channels? | 3.3 | 11 | Citations (PDF) |
| 263 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 2.1 | 4,360 | Citations (PDF) |
| 264 | Optimizing blood pressure control in hypertension: The need to use ABPM | 1.7 | 10 | Citations (PDF) |
| 265 | Vascular and Renal Hemodynamic Changes after Renal Denervation | 4.2 | 58 | Citations (PDF) |
| 266 | Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension | 18.0 | 242 | Citations (PDF) |
| 267 | Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey | 2.0 | 18 | Citations (PDF) |
| 268 | 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) | 2.1 | 841 | Citations (PDF) |
| 269 | Local application of tropicamide 0.5% reduces retinal capillary blood flow | 1.7 | 33 | Citations (PDF) |
| 270 | An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors | 1.8 | 2 | Citations (PDF) |
| 271 | Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring | 2.5 | 19 | Citations (PDF) |
| 272 | Review of direct renin inhibition by aliskiren | 6.1 | 20 | Citations (PDF) |
| 273 | Haemoglobin and vascular function in the human retinal vascular bed | 2.1 | 5 | Citations (PDF) |
| 274 | Patients with treatment-resistant hypertension report increased stress and anxiety | 2.1 | 32 | Citations (PDF) |
| 275 | Clinical situations associated with difficult-to-control hypertension | 2.1 | 20 | Citations (PDF) |
| 276 | Catheter-based Renal Sympathetic Denervation – Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives | 1.4 | 8 | Citations (PDF) |
| 277 | Updated ESH position paper on interventional therapy of resistant hypertension | 3.0 | 61 | Citations (PDF) |
| 278 | Risks Versus Benefits of Withdrawing Antihypertensive Therapy | 2.8 | 2 | Citations (PDF) |
| 279 | Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis | 2.1 | 2 | Citations (PDF) |
| 280 | Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study | 6.1 | 22 | Citations (PDF) |
| 281 | Tonic Postganglionic Sympathetic Inhibition Induced by Afferent Renal Nerves? | 6.6 | 44 | Citations (PDF) |
| 282 | Chronobiologie des Blutdrucks und Chronopharmakotherapie der arteriellen Hypertonie | 0.2 | 3 | Citations (PDF) |
| 283 | Diagnostik, Bedeutung, Prävention und Therapie einer Mikroalbuminurie | 0.2 | 1 | Citations (PDF) |
| 284 | Die Rolle der retinalen Mikrozirkulation in der Hypertonie | 0.2 | 2 | Citations (PDF) |
| 285 | Impaired Increase of Retinal Capillary Blood Flow to Flicker Light Exposure in Arterial Hypertension | 6.6 | 29 | Citations (PDF) |
| 286 | Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany | 2.2 | 18 | Citations (PDF) |
| 287 | Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation | 4.2 | 11 | Citations (PDF) |
| 288 | Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension | 2.1 | 147 | Citations (PDF) |
| 289 | Postchallenge hyperglycemia is closely related with early vascular damage in overweight and obese patients | 2.1 | 1 | Citations (PDF) |
| 290 | ESH Position Paper | 2.1 | 227 | Citations (PDF) |
| 291 | 23
Na Magnetic Resonance Imaging of Tissue Sodium | 6.6 | 257 | Citations (PDF) |
| 292 | Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension | 2.8 | 16 | Citations (PDF) |
| 293 | Salt intake determines retinal arteriolar structure in treatment resistant hypertension independent of blood pressure | 1.5 | 15 | Citations (PDF) |
| 294 | Current status of renal denervation in resistant hypertension | 2.3 | 2 | Citations (PDF) |
| 295 | Hypertensive Krise | 0.0 | 0 | Citations (PDF) |
| 296 | Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension | 18.0 | 447 | Citations (PDF) |
| 297 | Salt and Hypertension: Is Salt Dietary Reduction Worth the Effort? | 2.0 | 167 | Citations (PDF) |
| 298 | Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo | 2.5 | 20 | Citations (PDF) |
| 299 | Rosuvastatin improves pulse wave reflection by restoring endothelial function | 2.5 | 17 | Citations (PDF) |
| 300 | Renal Denervation in a Hypertensive Patient With End‐Stage Renal Disease and Small Arteries: A Direction for Future Research | 2.0 | 38 | Citations (PDF) |
| 301 | Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension | 6.6 | 300 | Citations (PDF) |
| 302 | 25-Hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment | 2.8 | 15 | Citations (PDF) |
| 303 | Validation of a therapeutic scheme for the treatment of resistant hypertension | 2.3 | 21 | Citations (PDF) |
| 304 | The Fcγ receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia | 1.5 | 11 | Citations (PDF) |
| 305 | Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men | 1.2 | 33 | Citations (PDF) |
| 306 | New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans | 2.1 | 62 | Citations (PDF) |
| 307 | Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation | 2.1 | 14 | Citations (PDF) |
| 308 | Physician attitudes to blood pressure control | 2.1 | 41 | Citations (PDF) |
| 309 | REAL LIFE ANALYSIS OF BLOOD PRESSURE REDUCTION IN OVER 5000 RESISTANT HYPERTENSIVE PATIENTS:RESULTS FROM THE 3A REGISTRY | 2.1 | 0 | Citations (PDF) |
| 310 | BLOOD PRESSURE REDUCTION IN CARDIO-RENAL HYPERTENSIVE PATIENTS: RESULTS FROM THE 3A REGISTRY | 2.1 | 0 | Citations (PDF) |
| 311 | REAL LIFE ANALYSIS AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS CLASSIFIED BY THE SEVERITY OF BLOOD PRESSURE - RESULTS FROM THE 3A REGISTRY | 2.1 | 0 | Citations (PDF) |
| 312 | BLOOD PRESSURE REDUCTION IN 7000 ELDERLY HYPERTENSIVE PATIENTS: RESULTS FROM THE 3A REGISTRY | 2.1 | 1 | Citations (PDF) |
| 313 | Hochdrucktherapie: Von Barrieren und Hoffnungen | 0.0 | 0 | Citations (PDF) |
| 314 | Cerebral Microangiopathy in Treatment‐Resistant Hypertension | 2.0 | 9 | Citations (PDF) |
| 315 | Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease | 0.4 | 247 | Citations (PDF) |
| 316 | Vergleich von frühen Veränderungen der retinalen Mikrostrombahn und Mikroalbuminurie als Zeichen eines erhöhten kardiovaskulären Risikos | 0.4 | 1 | Citations (PDF) |
| 317 | Reduction in Basal Nitric Oxide Activity Causes Albuminuria | 4.2 | 29 | Citations (PDF) |
| 318 | Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events | 16.5 | 491 | Citations (PDF) |
| 319 | Rosuvastatin in Diabetic Hemodialysis Patients | 0.4 | 118 | Citations (PDF) |
| 320 | Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels | 2.1 | 33 | Citations (PDF) |
| 321 | Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) | 18.0 | 165 | Citations (PDF) |
| 322 | Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension | 3.0 | 30 | Citations (PDF) |
| 323 | Remodeling of Retinal Small Arteries in Hypertension | 2.0 | 62 | Citations (PDF) |
| 324 | Beyond salt: lifestyle modifications and blood pressure | 2.2 | 118 | Citations (PDF) |
| 325 | Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension | 2.1 | 48 | Citations (PDF) |
| 326 | Renal protection in diabetes: lessons from ONTARGET® | 9.4 | 29 | Citations (PDF) |
| 327 | Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial | 2.2 | 42 | Citations (PDF) |
| 328 | Nitric Oxide and Reactive Hyperemia: Role of Location and Duration of Ischemia | 2.0 | 20 | Citations (PDF) |
| 329 | Angiotensin II-Type 2 Receptor: Emerging Target for Cardiovascular Protection | 2.0 | 1 | Citations (PDF) |
| 330 | Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises | 6.6 | 25 | Citations (PDF) |
| 331 | Renal resistive index--a valid tool to assess renal endothelial function in humans? | 0.8 | 23 | Citations (PDF) |
| 332 | Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care | 2.1 | 10 | Citations (PDF) |
| 333 | Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome | 0.8 | 75 | Citations (PDF) |
| 334 | Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension | 2.1 | 6 | Citations (PDF) |
| 335 | Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition | 2.3 | 420 | Citations (PDF) |
| 336 | The Role of Fixed-Dose Combination Therapy with Drugs that Target the Renin-Angiotensin System in the Hypertension Paradigm | 3.1 | 14 | Citations (PDF) |
| 337 | Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial | 62.1 | 2,120 | Citations (PDF) |
| 338 | Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients | 2.5 | 16 | Citations (PDF) |
| 339 | Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy | 0.5 | 14 | Citations (PDF) |
| 340 | Hypertension and atrial fibrillation with emphasis on prevention | 1.7 | 2 | Citations (PDF) |
| 341 | Cardiovascular disease in patients with renal disease: the role of statins | 2.1 | 35 | Citations (PDF) |
| 342 | Gender is related to alterations of renal endothelial function in type 2 diabetes | 0.8 | 20 | Citations (PDF) |
| 343 | Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren | 18.0 | 130 | Citations (PDF) |
| 344 | Wall-to-Lumen Ratio of Retinal Arterioles and Arteriole-to-Venule Ratio of Retinal Vessels in Patients with Cerebrovascular Damage 2009, 50, 4351 | | 68 | Citations (PDF) |
| 345 | Wall-to-Lumen Ratio of Retinal Arterioles as a Tool to Assess Vascular Changes | 6.6 | 64 | Citations (PDF) |
| 346 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 2.1 | 1,529 | Citations (PDF) |
| 347 | Hypertension and Diabetes | 6.2 | 0 | Citations (PDF) |
| 348 | Renal Vascular Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus | 1.4 | 38 | Citations (PDF) |
| 349 | The role of statins in the treatment of the metabolic syndrome | 4.7 | 20 | Citations (PDF) |
| 350 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria | 3.3 | 13 | Citations (PDF) |
| 351 | Therapieoptimierung bei diabetischer Nephropathie | 0.4 | 2 | Citations (PDF) |
| 352 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 1.7 | 358 | Citations (PDF) |
| 353 | Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension | 2.1 | 30 | Citations (PDF) |
| 354 | Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial | 2.1 | 44 | Citations (PDF) |
| 355 | Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine | 2.1 | 43 | Citations (PDF) |
| 356 | Effect of Telmisartan on Renal Outcomes | 9.6 | 172 | Citations (PDF) |
| 357 | Erhaltene systolische Funktion und doch herzinsuffizient? | 0.0 | 5 | Citations (PDF) |
| 358 | Atrial Fibrillation and Renin–Angiotensin System Blockade in Hypertension | 2.3 | 1 | Citations (PDF) |
| 359 | Effekte der antihypertensiven Langzeittherapie mit Losartan auf den Blutdruck und die kognitive Funktion bei Patienten mit essentieller Hypertonie und weiteren zerebrovaskulären Risikofaktoren (AWARE-Beobachtungsstudie) | 0.1 | 5 | Citations (PDF) |
| 360 | Renin inhibitors, clinical experience | 3.7 | 19 | Citations (PDF) |
| 361 | A novel-1364A/C aquaporin 5 gene promoter polymorphism influences the responses to salt loading of the renin-angiotensin-aldosterone system and of blood pressure in young healthy men | 7.0 | 33 | Citations (PDF) |
| 362 | Impact of New-Onset Diabetes Mellitus on Development of Atrial Fibrillation and Heart Failure in High-Risk Hypertension (from the VALUE Trial) | 1.8 | 134 | Citations (PDF) |
| 363 | Blood Pressure Control in Patients With Comorbidities | 2.0 | 43 | Citations (PDF) |
| 364 | Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia | 1.5 | 30 | Citations (PDF) |
| 365 | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial | 62.1 | 1,497 | Citations (PDF) |
| 366 | Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients | 2.0 | 239 | Citations (PDF) |
| 367 | Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice | 3.5 | 47 | Citations (PDF) |
| 368 | Effects of Telmisartan and Ramipril on Adiponectin and Blood Pressure in Patients with Type 2 Diabetes | 2.0 | 29 | Citations (PDF) |
| 369 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension | 0.8 | 45 | Citations (PDF) |
| 370 | Response to Analysis of Carotid and Ophthalmic Flow Velocity Waveforms | 6.6 | 0 | Citations (PDF) |
| 371 | (Pro)Renin Receptor Peptide Inhibitor “Handle-Region” Peptide Does Not Affect Hypertensive Nephrosclerosis in Goldblatt Rats | 6.6 | 133 | Citations (PDF) |
| 372 | Effects of angiotensin II type 1-receptor blockade on retinal endothelial function | 2.1 | 10 | Citations (PDF) |
| 373 | Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial | 2.1 | 204 | Citations (PDF) |
| 374 | The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League | 2.1 | 199 | Citations (PDF) |
| 375 | Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans | 2.1 | 26 | Citations (PDF) |
| 376 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes | 2.1 | 19 | Citations (PDF) |
| 377 | Analysis of retinal arteriolar structure in never-treated patients with essential hypertension | 2.1 | 95 | Citations (PDF) |
| 378 | Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes | 1.2 | 17 | Citations (PDF) |
| 379 | Cardiovascular Risk Management – Efficacy of Manidipine in Hypertension and Beyond | 2.3 | 1 | Citations (PDF) |
| 380 | Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease | 0.8 | 52 | Citations (PDF) |
| 381 | Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy | 0.8 | 58 | Citations (PDF) |
| 382 | Leitlinien 2007 der Europäischen Gesellschaften für Hypertonie und Kardiologie - Was hat sich geändert? | 0.2 | 3 | Citations (PDF) |
| 383 | Der Patient mit arterieller Hypertonie in der kardiologischen Facharztpraxis: Ergebnisse des Snapshot-Hypertonie-Registers | 0.2 | 9 | Citations (PDF) |
| 384 | Fourier Analysis of the Envelope of the Ophthalmic Artery Blood Flow Velocity | 6.6 | 20 | Citations (PDF) |
| 385 | 2007 Guidelines for the Management of Arterial Hypertension | 2.1 | 4,891 | Citations (PDF) |
| 386 | Increased Wall:Lumen Ratio of Retinal Arterioles in Male Patients With a History of a Cerebrovascular Event | 6.6 | 154 | Citations (PDF) |
| 387 | Auf den richtigen „Augenblick“ kommt es an | 0.0 | 0 | Citations (PDF) |
| 388 | 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension | 2.1 | 1,171 | Citations (PDF) |
| 389 | MDR1 genotype-dependent regulation of the aldosterone system in humans | 1.2 | 16 | Citations (PDF) |
| 390 | High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene | 2.1 | 15 | Citations (PDF) |
| 391 | Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan | 2.0 | 217 | Citations (PDF) |
| 392 | Left-Ventricular Structure and Function Are Influenced by Angiotensinogen Gene Polymorphism (−20 A/C) in Young Male Patients | 2.0 | 7 | Citations (PDF) |
| 393 | Effects of nitric oxide synthase inhibition and l-arginine on renal haemodynamics in young patients at high cardiovascular risk | 1.5 | 5 | Citations (PDF) |
| 394 | Renin-angiotensin system and cardiovascular risk | 62.1 | 634 | Citations (PDF) |
| 395 | Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension | 3.0 | 77 | Citations (PDF) |
| 396 | Albuminurie: ein kardiovaskulärer Risikoindikator | 0.1 | 4 | Citations (PDF) |
| 397 | Low-grade albuminuria and cardiovascular risk | 2.8 | 104 | Citations (PDF) |
| 398 | Renin inhibitors: Optimal strategy for renal protection | 4.7 | 6 | Citations (PDF) |
| 399 | Aliskiren – Clinical Benefits in the Management of Hypertension | 2.3 | 0 | Citations (PDF) |
| 400 | Valsartan and retinal endothelial function in elderly hypertensive patients | 1.7 | 11 | Citations (PDF) |
| 401 | EFFECT OF NOS INHIBITION ON RETINAL ARTERIAL AND CAPILLARY CIRCULATION IN EARLY ARTERIAL HYPERTENSION | 1.8 | 5 | Citations (PDF) |
| 402 | Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? | 2.1 | 39 | Citations (PDF) |
| 403 | EFFECT OF NOS INHIBITION ON RETINAL ARTERIAL AND CAPILLARY CIRCULATION IN EARLY ARTERIAL HYPERTENSION | 1.8 | 19 | Citations (PDF) |
| 404 | Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress | 5.3 | 25 | Citations (PDF) |
| 405 | „Shared Decision-Making” mit Bluthochdruckpatienten | 0.2 | 23 | Citations (PDF) |
| 406 | Bewährte und neue Parameter hypertensiver Endorganschäden | 0.2 | 1 | Citations (PDF) |
| 407 | Subklinische Albuminurie, Mikroalbuminurie und Proteinurie - akzeptierte kardiovaskuläre Risikomarker? | 0.2 | 8 | Citations (PDF) |
| 408 | Rapid Nongenomic Effects of Aldosterone on the Renal Vasculature in Humans | 6.6 | 66 | Citations (PDF) |
| 409 | Influences of Norepinephrine Transporter Function on the Distribution of Sympathetic Activity in Humans | 6.6 | 52 | Citations (PDF) |
| 410 | Aliskiren: a clinical profile. | 6.1 | 7 | Citations (PDF) |
| 411 | Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers | 2.1 | 17 | Citations (PDF) |
| 412 | CYP3A5 genotype is associated with elevated blood pressure | 1.2 | 27 | Citations (PDF) |
| 413 | Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension | 2.1 | 82 | Citations (PDF) |
| 414 | Effects of sympathetic nerves and angiotensin II on renal sodium and water handling in rats with common bile duct ligature | 3.3 | 16 | Citations (PDF) |
| 415 | The role of non-haemodynamic factors of the genesis of LVH | 0.8 | 71 | Citations (PDF) |
| 416 | Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients | 18.0 | 496 | Citations (PDF) |
| 417 | Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients | 2.9 | 134 | Citations (PDF) |
| 418 | Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers | 2.0 | 125 | Citations (PDF) |
| 419 | Superoxide Scavenging Effects of -Acetylcysteine and Vitamin C in Subjects With Essential Hypertension | 2.0 | 50 | Citations (PDF) |
| 420 | Changes in plasma renin match the antihypertensive effects of aliskiren in patients with hypertension: Placebo/irbesartan-controlled trial with the orally active renin inhibitor aliskiren | 2.0 | 5 | Citations (PDF) |
| 421 | The role of nitric oxide in the regulation of glomerular haemodynamics in humans | 0.8 | 49 | Citations (PDF) |
| 422 | Effect of Irbesartan Versus Atenolol on Left Ventricular Mass and Voltage | 6.6 | 52 | Citations (PDF) |
| 423 | Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients | 5.9 | 152 | Citations (PDF) |
| 424 | Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes | 0.8 | 34 | Citations (PDF) |
| 425 | Letters to the Editor | 6.6 | 0 | Citations (PDF) |
| 426 | Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients | 5.3 | 53 | Citations (PDF) |
| 427 | Intensive training of patients with hypertension is effective in modifying lifestyle risk factors | 2.5 | 20 | Citations (PDF) |
| 428 | Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension | 2.1 | 12 | Citations (PDF) |
| 429 | Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial | 2.0 | 525 | Citations (PDF) |
| 430 | The effect of valsartan on the endothelial function of the retinal capillary bed in elderly hypertensive subjects | 2.0 | 0 | Citations (PDF) |
| 431 | Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients | 2.0 | 8 | Citations (PDF) |
| 432 | Picxel: perindopril/indapamide has a greater benefit on left ventricular hypertrophy than enalapril | 2.0 | 0 | Citations (PDF) |
| 433 | Antihypertensive efficacy of indapamide SR vs candesartan and amlodipine in isolated systolic hypertensive patients | 2.0 | 5 | Citations (PDF) |
| 434 | The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men | 2.0 | 1 | Citations (PDF) |
| 435 | Renal endothelial effects of antihypertensive therapy | 2.2 | 7 | Citations (PDF) |
| 436 | DETERMINANTS OF THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY ON TREATED HYPERTENSIVES | 2.1 | 3 | Citations (PDF) |
| 437 | RAPID NONGENOMIC EFFECTS OF ALDOSTERONE IN ESSENTIAL HYPERTENSION | 2.1 | 0 | Citations (PDF) |
| 438 | IMPAIRED STIMULATED NO-ACTIVITY BY DARBEPOIETIN IN HYPERTENSIVE SUBJECTS | 2.1 | 0 | Citations (PDF) |
| 439 | CARDIAC STRUCTURAL ADAPTATION OF THE LEFT AND RIGHT VENTRICLE IN EARLY STAGES OF ESSENTIAL HYPERTENSION | 2.1 | 0 | Citations (PDF) |
| 440 | THE EFFECT OF VALSARTAN ON THE ENDOTHELIAL FUNCTION OF THE RETINAL CAPILLARY BED | 2.1 | 0 | Citations (PDF) |
| 441 | EFFECTS OF ULTRA HIGH DOSE CANDESARTAN (64MG) ON PROTEINURIA | 2.1 | 0 | Citations (PDF) |
| 442 | PLATELET P-SELECTIN AND PLASMA LEVELS OF CIRCULATING CYTOKINES IN YOUNG PATIENTS WITH MILD ESSENTIAL HYPERTENSION | 2.1 | 0 | Citations (PDF) |
| 443 | A SINGLE NUCLEOTIDE POLYMORPHISM (SNP) IN THE HUMAN GLUTATHIONE S-TRANSFERASE MU TYPE 4 GENE (GSTM 4) IS ASSOCIATED WITH IMPAIRED ENDOTHELIAL FUNCTION AND ARTERIAL HYPERTENSION | 2.1 | 0 | Citations (PDF) |
| 444 | Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia | 4.7 | 81 | Citations (PDF) |
| 445 | Functional Relevance of Aldosterone for the Determination of Left Ventricular Mass | 1.8 | 18 | Citations (PDF) |
| 446 | Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress | 5.3 | 15 | Citations (PDF) |
| 447 | Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension | 2.0 | 37 | Citations (PDF) |
| 448 | Effect of AT1 receptor blockade on endothelial function in essential hypertension | 2.0 | 103 | Citations (PDF) |
| 449 | Aldosterone-induced cardiac damage: focus on blood pressure independent effects | 2.0 | 102 | Citations (PDF) |
| 450 | Elevation of sympathetic activity by eprosartan in young male subjects | 2.0 | 29 | Citations (PDF) |
| 451 | AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain | 3.0 | 17 | Citations (PDF) |
| 452 | Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature | 6.6 | 118 | Citations (PDF) |
| 453 | Vitamin C augments the renal response to L-arginine in smokers | 0.8 | 14 | Citations (PDF) |
| 454 | Endothelfunktion im Nierenstromgebiet
des Menschen | 0.2 | 2 | Citations (PDF) |
| 455 | Kontrolle des systolischen
Blutdrucks in der
VALUE-Studie nach 12 Monaten | 0.2 | 0 | Citations (PDF) |
| 456 | Reply | 0.8 | 0 | Citations (PDF) |
| 457 | Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics | 0.8 | 10 | Citations (PDF) |
| 458 | Beeinflussen COX-2-Inhibitoren das kardiovaskuläre
Risiko? | 0.2 | 3 | Citations (PDF) |
| 459 | AT1-receptor blockade improves augmentation index | 2.1 | 57 | Citations (PDF) |
| 460 | Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension | 2.1 | 29 | Citations (PDF) |
| 461 | Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects | 2.1 | 21 | Citations (PDF) |
| 462 | Assessment of endothelial function of the renal vasculature in human subjects | 2.0 | 75 | Citations (PDF) |
| 463 | Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical NG, NG-dimethylarginine in human essential hypertension1 | 2.0 | 135 | Citations (PDF) |
| 464 | Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? | 2.9 | 22 | Citations (PDF) |
| 465 | Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension11See Editorial by Noris and Remuzzi, p. 1545. | 5.3 | 46 | Citations (PDF) |
| 466 | Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans | 2.3 | 87 | Citations (PDF) |
| 467 | Aldosterone synthase (CYP11B2) −344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension | 2.3 | 51 | Citations (PDF) |
| 468 | Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks | 2.3 | 105 | Citations (PDF) |
| 469 | Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ace inhibition | 2.0 | 2 | Citations (PDF) |
| 470 | The Kidney in Congestive Heart Failure: Renal Adverse Event Rate of Treatment | 2.0 | 7 | Citations (PDF) |
| 471 | Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients | 0.8 | 54 | Citations (PDF) |
| 472 | Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial | 0.8 | 170 | Citations (PDF) |
| 473 | Effects of oral contraceptives on vascular endothelium in premenopausal women | 2.4 | 31 | Citations (PDF) |
| 474 | Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis | 6.2 | 25 | Citations (PDF) |
| 475 | Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature? | 6.2 | 29 | Citations (PDF) |
| 476 | Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature? | 6.2 | 9 | Citations (PDF) |
| 477 | Lack of association between polymorphisms of angiotensin II receptor genes and response to short-term angiotensin II infusion | 2.1 | 13 | Citations (PDF) |
| 478 | PROSPECTIVE ANALYSIS OF THE VALUE OF 24-HOUR AMBULATORY BLOOD PRESSURE ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION | 2.1 | 41 | Citations (PDF) |
| 479 | Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase | 2.1 | 69 | Citations (PDF) |
| 480 | Impaired endothelial function in arterial hypertension and hypercholesterolemia | 2.1 | 146 | Citations (PDF) |
| 481 | Hypertension and the heart | 2.5 | 83 | Citations (PDF) |
| 482 | Effects of oral contraceptives on vascular endothelium in premenopausal women | 2.4 | 34 | Citations (PDF) |
| 483 | Vascular reactivity in patients with preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome | 2.4 | 25 | Citations (PDF) |
| 484 | Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects | 1.8 | 58 | Citations (PDF) |
| 485 | Ergebnisse der Intensiv-Hypertonieschulung
des Instituts für präventive Medizin | 0.2 | 11 | Citations (PDF) |
| 486 | Enhanced antinatriuresis in response to angiotensin II in essential hypertension | 2.0 | 11 | Citations (PDF) |
| 487 | Regression of left ventricular hypertrophy by at1 receptor blockade in renal transplant recipients | 2.0 | 18 | Citations (PDF) |
| 488 | Determinants of left ventricular structure after kidney transplantation | 0.7 | 6 | Citations (PDF) |
| 489 | Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients | 1.5 | 35 | Citations (PDF) |
| 490 | Lipid-lowering therapy with cerivastatin improves endothelial function after 2 weeks | 1.5 | 0 | Citations (PDF) |
| 491 | Renal cell carcinoma and diuretics - should one restrict the use of diuretics? | 0.8 | 1 | Citations (PDF) |
| 492 | Not all left ventricular hypertrophy is created equal | 0.8 | 10 | Citations (PDF) |
| 493 | Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure | 2.0 | 0 | Citations (PDF) |
| 494 | Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure | 2.0 | 24 | Citations (PDF) |
| 495 | Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects | 2.9 | 25 | Citations (PDF) |
| 496 | 825T allele of the G-protein β3 subunit gene (GNB3) is associated with impaired left ventricular diastolic filling in essential hypertension | 2.1 | 32 | Citations (PDF) |
| 497 | Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects | 2.1 | 7 | Citations (PDF) |
| 498 | Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans | 2.1 | 21 | Citations (PDF) |
| 499 | Diuretikatherapie und das Risiko für Nierenzellkarzinome | 0.2 | 0 | Citations (PDF) |
| 500 | Effects of naloxone on hemodynamic and sympathetic nerve responses to pain in normotensive vs. borderline hypertensive men | 2.5 | 58 | Citations (PDF) |
| 501 | Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approachFocus on treatment by antihypertensive agents | 2.0 | 61 | Citations (PDF) |
| 502 | Does Lipoprotein(a) Impair Endothelial Function? | 2.3 | 61 | Citations (PDF) |
| 503 | Vasodilatory Capacity of Forearm Resistance Vessels Is Augmented in Hypercholesterolemic Patients After Treatment with Fluvastatin | 1.9 | 12 | Citations (PDF) |
| 504 | Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension | 2.2 | 32 | Citations (PDF) |
| 505 | Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) | 0.8 | 172 | Citations (PDF) |
| 506 | Salt | 8.1 | 70 | Citations (PDF) |
| 507 | Dietary salt intake and left ventricular hypertrophy | 0.8 | 13 | Citations (PDF) |
| 508 | Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation | 0.8 | 13 | Citations (PDF) |
| 509 | Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension? | 0.8 | 22 | Citations (PDF) |
| 510 | Is Endothelial Function of the Radial Artery Altered in Human Essential Hypertension? | 2.0 | 18 | Citations (PDF) |
| 511 | Impact of α- Versus β-Blockers on Hypertensive Target Organ Damage Results of a Double-Blind, Randomized, Controlled Clinical Trial | 2.0 | 17 | Citations (PDF) |
| 512 | Renal and Systemic Hemodynamics in Black and White Hypertensive Patients | 2.0 | 4 | Citations (PDF) |
| 513 | E2 Determinants of left ventricular structure after kidney transplantation | 2.0 | 0 | Citations (PDF) |
| 514 | Endogenous erythropoietin correlates with blood pressure in essential hypertension | 1.4 | 16 | Citations (PDF) |
| 515 | Haemodynamics in hypertension | 0.2 | 2 | Citations (PDF) |
| 516 | Comparison of Early Target Organ Damage Between Blacks and Whites with Mild Systemic Arterial Hypertension | 1.8 | 4 | Citations (PDF) |
| 517 | Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. | 0.4 | 78 | Citations (PDF) |
| 518 | Treatment and post-treatment effects of α- versus β-receptor blockers on left ventricular structure and function in essential hypertension | 2.9 | 24 | Citations (PDF) |
| 519 | Overview of α1-Adrenoceptor Antagonism and Recent Advances in Hypertensive Therapy | 2.0 | 15 | Citations (PDF) |
| 520 | Subthreshold stimulation of a serotonin 5-HT3 reflex attenuates cardiovascular reflexes | 2.4 | 7 | Citations (PDF) |
| 521 | Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress | 2.1 | 10 | Citations (PDF) |
| 522 | Regression of Left Ventricular Hypertrophy-Reply | 16.5 | 0 | Citations (PDF) |
| 523 | Dietary Sodium and Blood Pressure | 16.5 | 0 | Citations (PDF) |
| 524 | Reversal of Left Ventricular Hypertrophy-Reply | 16.5 | 0 | Citations (PDF) |
| 525 | Reversal of Left Ventricular Hypertrophy in Essential Hypertension | 16.5 | 489 | Citations (PDF) |
| 526 | Preeclampsia — A State of Sympathetic Overactivity | 34.5 | 549 | Citations (PDF) |
| 527 | Angiotensin II Related to Sodium Excretion Modulates Left Ventricular Structure in Human Essential Hypertension | 18.0 | 121 | Citations (PDF) |
| 528 | Epicardial Bradykinin B2Receptors Elicit a Sympathoexcitatory Reflex in Rats | 6.6 | 25 | Citations (PDF) |
| 529 | Nerve-Mediated Antidiuresis and Antinatriuresis After Air-Jet Stress Is Modulated by Angiotensin II | 6.6 | 38 | Citations (PDF) |
| 530 | Predictors for hypertensive nephropathy | 2.1 | 27 | Citations (PDF) |
| 531 | Compliance großer elastischer Arterien nach blutdrucksenkender Therapie mit einem Calciumantagonisten | 0.2 | 2 | Citations (PDF) |
| 532 | Improved classification of dippers by individualized analysis of ambulatory blood pressure profiles | 2.0 | 63 | Citations (PDF) |
| 533 | Gender-specific cardiovascular adaptation due to circadian blood pressure variations in essential hypertension | 2.0 | 57 | Citations (PDF) |
| 534 | Central blood volume: A determinant of early cardiac adaptation in arterial hypertension? | 2.3 | 19 | Citations (PDF) |
| 535 | 781-6 Reversal of Left Ventricular Hypertrophy in Essential Hypertension: Meta-Analysis of Studies with High Scientific Quality | 2.3 | 4 | Citations (PDF) |
| 536 | 781-3 Do Racial Differences Effect the Indices of Target Organ Damage in Arterial Hypertension? | 2.3 | 1 | Citations (PDF) |
| 537 | NORMALIZATION OF CIRCADIAN BLOOD PRESSURE PROFILES AFTER RENAL TRANSPLANTATION | 2.1 | 60 | Citations (PDF) |
| 538 | NORMALIZATION OF CIRCADIAN BLOOD PRESSURE PROFILES AFTER RENAL TRANSPLANTATION | 2.1 | 2 | Citations (PDF) |
| 539 | Effects of Bromocriptine on Cardiovascular Regulation in Healthy Humans | 6.6 | 24 | Citations (PDF) |
| 540 | Salt intake, blood pressure, and cardiovascular structure | 2.1 | 16 | Citations (PDF) |
| 541 | Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy | 1.8 | 31 | Citations (PDF) |
| 542 | Nephroprotection by Antihypertensive Agents | 2.0 | 20 | Citations (PDF) |
| 543 | Obesity and hypertension | 2.2 | 9 | Citations (PDF) |
| 544 | Nephroprotection by Antihypertensive Agents | 2.0 | 0 | Citations (PDF) |
| 545 | Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy | 1.8 | 14 | Citations (PDF) |
| 546 | Obesity as a determinant for response to antihypertensive treatment. | 0.1 | 48 | Citations (PDF) |
| 547 | A centripetal shift in intravascular volume triggers the onset of early cardiac adaptation in hypertension | 2.1 | 7 | Citations (PDF) |
| 548 | Improved prediction of left ventricular mass from ambulatory blood pressure monitoring using average tension-time index | 2.1 | 8 | Citations (PDF) |
| 549 | Renal Hemodynamics and Cardiovascular Reactivity in the Prehypertensive Stage | 2.4 | 12 | Citations (PDF) |
| 550 | Obese hypertensive patients are less effectively treated than lean hypertensives | 2.1 | 1 | Citations (PDF) |
| 551 | Hypertensive Heart Disease | 2.0 | 1 | Citations (PDF) |
| 552 | Impact of Antihypertensive Therapy With Isradipine and Metoprolol on Early Markers of Hypertensive Nephropathy | 2.0 | 20 | Citations (PDF) |
| 553 | Determinants of ventricular ectopy in hypertensive cardiac hypertrophy | 2.9 | 24 | Citations (PDF) |
| 554 | Stress response pattern in obesity and systemic hypertension | 1.8 | 26 | Citations (PDF) |
| 555 | Hypertensive Heart Disease | 2.0 | 14 | Citations (PDF) |
| 556 | Elevated Serum Activity of N-Acetyl-β-Glucosaminidase in Essential Hypertension: Diagnostic Value and Reversal to Normal Values After Antihypertensive Therapy | 1.4 | 9 | Citations (PDF) |
| 557 | Antihypertensive Therapy | 16.5 | 15 | Citations (PDF) |
| 558 | 141. Isometric stress impairs the beneficial hemodynamic profile of obesity hypertension | 2.1 | 0 | Citations (PDF) |
| 559 | Arterielle Hypertonie, linksventrikuläre Hypertrophie und plötzlicher Herztod | 0.2 | 5 | Citations (PDF) |
| 560 | When is discontinuation of antihypertensive therapy indicated? | 2.1 | 4 | Citations (PDF) |
| 561 | Relation of Hemodynamic Reaction During Stress to Left Ventricular Hypertrophy in Essential Hypertension | 2.0 | 17 | Citations (PDF) |
| 562 | Glomerular Hyperfiltration Indicates Early Target Organ Damage in Essential Hypertension | 16.5 | 100 | Citations (PDF) |
| 563 | Reversal of Left Ventricular Hypertrophy | 2.0 | 10 | Citations (PDF) |
| 564 | Reversal of Left Ventricular Hypertrophy | 2.0 | 5 | Citations (PDF) |
| 565 | Risk Reduction Following Regression of Cardiac Hypertrophy | 0.3 | 4 | Citations (PDF) |
| 566 | Hypertension and Sudden Death | 8.1 | 99 | Citations (PDF) |
| 567 | Salt Intake Is Related to the Process of Myocardial Hypertrophy in Essential Hypertension | 16.5 | 7 | Citations (PDF) |
| 568 | Efficacy of four antihypertensive drugs (clonidine, enalapril, nitrendipine, oxprenolol) on stress blood pressure | 1.8 | 16 | Citations (PDF) |
| 569 | Cardiac performance after reduction of myocardial hypertrophy | 2.0 | 67 | Citations (PDF) |
| 570 | Sex differences in cardiac adaptation to essential hypertension | 2.2 | 71 | Citations (PDF) |
| 571 | Cardiac performance after reduction of myocardial hypertrophy☆ | 2.0 | 0 | Citations (PDF) |
| 572 | Hemodynamic, humoral and volume findings in systemic hypertension with isolated ventricular septal hypertrophy | 1.8 | 12 | Citations (PDF) |
| 573 | Myocardial contractility and left ventricular function in obese patients with essential hypertension | 1.8 | 100 | Citations (PDF) |
| 574 | Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension | 1.8 | 63 | Citations (PDF) |
| 575 | Ambulatory blood pressure monitoring: Practical considerations | 2.9 | 30 | Citations (PDF) |
| 576 | Angiotensin Converting Enzyme Inhibitors: Disparities in the Mechanism of their Antihypertensive Effect | 2.0 | 16 | Citations (PDF) |
| 577 | Sodium intake modulates left ventricular hypertrophy in essential hypertension | 2.1 | 23 | Citations (PDF) |
| 578 | 2 Glomerular hyperfiltration in essential hypertension | 2.1 | 0 | Citations (PDF) |
| 579 | Disparate Cardiovascular Findings in Men and Women with Essential Hypertension | 9.6 | 149 | Citations (PDF) |
| 580 | Obesity Hypertension | 3.1 | 28 | Citations (PDF) |
| 581 | Serum Uric Acid in Renovascular Hypertension: Reduction Following Surgical Correction | 0.9 | 16 | Citations (PDF) |
| 582 | Disparate hemodynamic responses to mental challenge after antihypertensive therapy with beta blockers and calcium entry blockers | 2.0 | 101 | Citations (PDF) |
| 583 | Biventricular cardiac hypertrophy in essential hypertension | 2.9 | 55 | Citations (PDF) |
| 584 | Immediate Hemodynamic Response to Furosemide in Patients Undergoing Chronic Hemodialysis | 1.4 | 22 | Citations (PDF) |
| 585 | Heterogeneous pathophysiology of essential hypertension: Implications for therapy | 2.9 | 5 | Citations (PDF) |
| 586 | Use of diuretic agents in obese or black patients with systemic hypertension | 1.8 | 13 | Citations (PDF) |
| 587 | Pathophysiology of Hypertension in the Elderly | 1.5 | 17 | Citations (PDF) |
| 588 | Risks for Arterial Hypertension | 1.5 | 10 | Citations (PDF) |
| 589 | Angiotensin Blockade to Reduce Microvascular Damage in Diabetes Mellitus | 0.1 | 7 | Citations (PDF) |
| 590 | End Organ Damage In Hypertension | 0.1 | 115 | Citations (PDF) |
| 591 | In Reply | 0.1 | 0 | Citations (PDF) |
| 592 | Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients | 2.0 | 4 | Citations (PDF) |
| 593 | Renal denervation increases capillary density in hypertensive patients | 2.0 | 2 | Citations (PDF) |
| 594 | Effects of intrarenal afferent stimulation by bradykinin on renal sympathetic nerve activity: tonic inhibition contributing to renal function | 2.3 | 0 | Citations (PDF) |
| 595 | 2025 Update on resistant hypertension in CKD: where do we stand and where do we go? | 3.4 | 1 | Citations (PDF) |
| 596 | Sustained Blood Pressure Reduction Following Ultrasound Renal Denervation in Patients with CKD: 12-Month Follow-Up Data from the RDN-CKD Study | 0.4 | 0 | Citations (PDF) |
| 597 | Impact of baseline systolic blood pressure on blood pressure changes following renal denervation | 3.0 | 2 | Citations (PDF) |
| 598 | Renal Denervation in Patients With Moderate to Severe Chronic Kidney Disease | 6.6 | 6 | Citations (PDF) |
| 599 | Effect of renal denervation on the lipid profile in patients with or without coronary artery disease | 2.8 | 0 | Citations (PDF) |
| 600 | Impact of centrally acting sympatholytic agents on the blood pressure response to renal denervation | 2.1 | 0 | Citations (PDF) |
| 601 | Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia | 1.5 | 0 | Citations (PDF) |
| 602 | Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives | 1.5 | 0 | Citations (PDF) |
| 603 | 300.05 Radiofrequency Renal Denervation Reduces Hypertensive Urgencies with Potential Healthcare Cost Savings in the United States: Two-Year Pooled Analysis of Randomized, Sham Controlled Trials | 3.0 | 0 | Citations (PDF) |
| 604 | 26-A-15422-ACC REDUCING HYPERTENSIVE URGENCY WITH RADIOFREQUENCY RENAL DENERVATION THROUGH THREE YEARS: INSIGHTS FROM THE SPYRAL HTN-ON AND OFF MED TRIALS | 2.3 | 0 | Citations (PDF) |
| 605 | Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program | 3.0 | 0 | Citations (PDF) |
| 606 | RENAL DENERVATION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: FIRST RESULTS FROM THE RANDOMIZED RDN-ADPKD STUDY | 2.1 | 0 | Citations (PDF) |
| 607 | EARLY CHANGES IN THE MACROCIRCULATION PRECEDE MICROCIRCULATORY ADAPTATION AFTER RENAL TRANSPLANTATION | 2.1 | 0 | Citations (PDF) |
| 608 | THREE-YEAR OUTCOMES OF RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH HYPERTENSION-MEDIATED ORGAN DAMAGE: INSIGHTS FROM THE GLOBAL SYMPLICITY REGISTRY DEFINE | 2.1 | 0 | Citations (PDF) |
| 609 | THE CLINICAL BENEFIT AFTER RADIOFREQUENCY RENAL DENERVATION: POOLED 36-MONTH RESULTS FROM THE SPYRAL CLINICAL PROGRAM | 2.1 | 0 | Citations (PDF) |
| 610 | BLOOD PRESSURE DECREASE FOUR WEEKS AFTER INTERVENTIONAL TREATMENT OF AORTIC RECOARCTATION IS ASSOCIATED WITH IMPROVED VASCULAR REMODELING | 2.1 | 0 | Citations (PDF) |
| 611 | SIGNIFICANT REDUCTIONS IN ALBUMINURIA IN PATIENTS WITH HYPERTENSIVE RENAL DISEASE AFTER RADIOFREQUENCY RENAL DENERVATION: RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY DEFINE | 2.1 | 0 | Citations (PDF) |
| 612 | 12-MONTHS FOLLOW-UP DATA FROM THE RDN-CKD STUDY: BLOOD PRESSURE REDUCTION AND RENAL FUNCTION FOLLOWING ULTRASOUND RENAL DENERVATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 3 | 2.1 | 0 | Citations (PDF) |
